Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug discovery and p53.

David P Lane1, Ted R Hupp

  • 1Cancer Research UK Laboratories, Department of Surgery and Molecular Oncology, University of Dundee, Dundee, Scotland DD1 9SY, UK. d.p.lane@dundee.ac.uk

Drug Discovery Today
|April 12, 2003
PubMed
Summary

Restoring tumor suppressor gene activity, like p53, is a novel cancer drug target. These proteins are intrinsically disordered, enabling small molecules to restore their function and halt cancer cell proliferation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Cell death & disease·2025
Same author

Confirmation by conformation: rescue of mutant p53 in AML.

Blood·2025
Same author

Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

Cancer research·2025
Same author

CDK11 inhibition induces cytoplasmic p21<sup>WAF1</sup> splice variant by p53 stabilisation and SF3B1 inactivation.

Molecular oncology·2025
Same author

Correction for: The regulation of p53 by phosphorylation: a model for how distinct signals Integrate into the p53 pathway.

Aging·2025
Same author

The legacy of a gentleman scientist: Pierre Hainaut.

Cell death and differentiation·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer research has advanced significantly due to identifying mutated oncogenes and tumor suppressor genes.
  • Targeting oncogenes with small molecules is established, but restoring tumor suppressor gene function is challenging.

Purpose of the Study:

  • To explore the potential of targeting intrinsically disordered tumor suppressor proteins with small molecules.
  • To investigate the molecular characteristics of p53 that enable therapeutic intervention.

Main Methods:

  • Review of recent advancements in cancer genetics and drug discovery.
  • Molecular characterization of the p53 protein, focusing on its structural and dynamic properties.

Main Results:

  • Many eukaryotic regulatory proteins, including tumor suppressors, are intrinsically disordered.
  • The p53 protein's conformational flexibility and instability are key to its function and post-translational modification.

Conclusions:

  • Intrinsically disordered proteins represent a viable, albeit unconventional, class of drug targets in cancer therapy.
  • Understanding the dynamic nature of proteins like p53 opens new avenues for developing small molecule therapeutics to restore their function.

Related Experiment Videos